Selank

What it is

Selank is the calming arm of the Russian-school nootropic-peptide pair. Its sister peptide Semax activates and clarifies; Selank smooths the noise. Together they cover the two most common cognitive complaints — I can’t focus and I can’t stop spiraling — with two distinct molecules, each with its own clinical track record.

Structurally, Selank is a synthetic heptapeptide modeled on tuftsin, an endogenous immunomodulatory tetrapeptide. The two extra prolines at the C-terminus stabilize the molecule so it actually survives long enough to work. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia for generalized anxiety disorder.

What’s unusual about Selank — and what makes it interesting as a category-of-one anxiolytic — is that it produces benzodiazepine-equivalent anxiolytic effect without any of the benzodiazepine trade-offs. No sedation. No cognitive blunting. No tolerance. No withdrawal. No dependence risk. In head-to-head clinical comparison against medazepam (a benzodiazepine), Selank matched the anxiolytic effect and beat the benzo on cognitive performance. That’s the entire pitch in one sentence.

How it works

Selank works through a triple pathway rather than a single dominant lever. This is part of why the effect profile is so different from SSRIs (which blunt-force inhibit monoamine reuptake) or benzodiazepines (which crank GABA-A wide open):

BDNF upregulation. Selank increases brain-derived neurotrophic factor, which drives synaptic plasticity, neuronal survival, and neurogenesis. This is the mechanistic basis for Selank’s fast onset of anxiolytic effect (1-3 days) — versus SSRIs, which require weeks. Anxiety symptoms that come from a depleted plasticity baseline respond to BDNF restoration much faster than to receptor-level neurotransmitter manipulation.

Enkephalinase inhibition → stabilized endogenous opioid tone. Enkephalinase is the enzyme that breaks down your body’s natural enkephalins — the endogenous opioids that govern mood stability, social bonding, and stress resilience. By slowing that breakdown, Selank lets your own opioid system run at a higher tonic level. No exogenous opioid; no dependence circuitry activated; just less depletion of your own.

Monoamine normalization — receptor sensitivity, not forced neurotransmitter flooding. Selank modulates serotonin and dopamine tone without the reuptake-blocking pharmacology of SSRIs/SNRIs. The mechanism distinction matters clinically: where SSRIs force more serotonin into the synapse regardless of receptor state, Selank’s serotonergic action appears to operate through upregulation of receptor sensitivity — making the brain more responsive to the serotonin it already produces rather than flooding a compromised system with more. This is the mechanistic explanation for why Selank provides anxiolytic effect in SSRI non-responders: their issue is typically receptor sensitivity, not serotonin availability. Selank addresses the actual problem.

Dopamine is the other arm: Selank modulates dopaminergic tone in cortical circuits. In anxiety, the dopamine/reward system is suppressed — everything feels threatening, nothing feels rewarding. This is why anxiety and depression co-occur so frequently: the same dopaminergic deficit (reduced motivation, reward-processing impairment, anhedonia) underlies both. Selank’s monoamine normalization addresses both simultaneously, without the anhedonia or libido suppression that SSRI-class serotonergic loading typically produces.

GABA-A: the open mechanistic question — partially resolved by the route-of-administration finding. There’s a real-looking contradiction in the published literature: some sources describe Selank as a positive allosteric modulator of GABA-A at a non-benzodiazepine site (specifically: +38% GABA-A binding in mouse frontal cortex); others describe it as not a direct GABA-A agonist at all. The contradiction substantially resolves once you note the route of administration — see “Route changes the receptor” below. The GABA-binding finding is the intraperitoneal/injectable route signature; the intranasal route doesn’t show the GABA effect but instead increases NMDA receptor binding. Same molecule, different delivery, different receptor target. The practical outcome remains consistent across all routes: no benzodiazepine-class adverse profile — no sedation, no tolerance, no withdrawal. Whatever Selank does at GABA-A on the injectable route, it isn’t what Xanax does.

Tuftsin-analog immunomodulation. Selank retains some of tuftsin’s immune activity — enhanced NK cell function, increased interferon production (Ershov et al. 2009, PMID 19882898), and Th1/Th2 cytokine balance modulation in anxiety-asthenic patients (Uchakina et al. 2008, PMID 18577961). This is a secondary effect for cognitive/anxiety use, but it’s the basis for the “use with caution in active autoimmune disease or on immunosuppressants” caveat.

Neuroinflammation context (what Selank’s anti-inflammatory mechanism actually is). Neuroinflammation is a real and significant driver of chronic anxiety — pro-inflammatory cytokines crossing the blood-brain barrier activate microglia, which impair GABAergic signaling and perpetuate the anxiety cascade. Selank addresses this through its immunomodulatory mechanisms above, and IL-10 / TGF-β upregulation is biologically consistent with its anti-inflammatory profile. What the real data does NOT support: claims that Selank reduces TNF-α or IL-6 specifically in cerebrospinal fluid — no Selank CSF study has been found, and that specific claim is unverified and contradicted by the available cytokine literature. Selank’s neuroinflammatory benefit appears to operate through its enkephalinase/opioid-tone and interferon pathways rather than direct pro-inflammatory cytokine suppression.

Vagal tone / parasympathetic enhancement. Selank’s broad neurological effects may extend to autonomic nervous system tone via increased sensitivity of nucleus tractus solitarius (NTS) neurons — relay stations for vagal input that operate through both GABA and acetylcholine signaling. Vagal tone (measurable via heart rate variability) is the physiological substrate for the parasympathetic system’s capacity to downregulate threat response after activation. Low vagal tone is a documented feature of anxiety disorders; high vagal tone correlates with greater stress resilience and faster recovery from acute stress. The NTS mechanism is a coherent extrapolation from Selank’s GABAergic and neurological profile, but no published Selank HRV study has been verified.

Route changes the receptor — intranasal vs injectable

This is a substantive mechanism finding that’s underappreciated in most peptide-creator content: the same Selank molecule activates different brain receptors depending on how you put it in your body. The route isn’t just a bioavailability or kinetics question — it changes which target the molecule preferentially engages, which changes the functional experience.

The mouse data (Volkova et al. 2018, PMID 29787664)

The cleanest primary-literature anchor: a 2018 mouse study in BALB/c and C57BL/6 strains directly compared intraperitoneal vs intranasal Selank on receptor binding in the frontal cortex and hippocampus. The signature finding:

Route	GABA receptor binding (frontal cortex)	NMDA receptor binding
Intraperitoneal (injectable proxy)	+38%	no significant change
Intranasal	no significant change	+23%

Follow-up work in Neurochemical Journal (Andreeva et al. 2020) replicated the finding across Selank, Semax, and Noopept — all three short anxiolytic/nootropic peptides show the same route-dependent receptor dominance. A 2023 follow-up extended the analysis to the glycine binding site on the NMDA receptor, the specific intranasal target — confirming that intranasal Selank decreases cortical glycine binding (18% in one strain, 53% in the other) and increases hippocampal glycine binding by 15%.

What this means clinically

The receptor-target shift maps cleanly onto the practitioner-observed difference in clinical experience:

Injectable Selank → GABA-dominant → slow systemic recalibration. The GABA system is the brain’s master “brake” — its tonic inhibitory control over the excitatory glutamate system. Increasing GABA receptor density in the frontal cortex over weeks of injected dosing produces the structural-baseline shift practitioners describe: lower-amplitude stress responses, less reactivity, baseline anxiety reduction that builds over a 10-week cycle and holds. You don’t feel it in the moment; you notice your baseline has shifted when you look back.

Intranasal Selank → NMDA-dominant → fast CNS-targeted performance window. The NMDA system is the glutamate / learning / neuroplasticity / synaptic-consolidation system. The intranasal route bypasses the blood-brain barrier via the olfactory nerve, gets to CSF within ~10 minutes, and activates NMDA receptors directly. This produces the acute, on-demand cognitive performance window practitioners describe: 10-minute onset, 2-4 hour effect, “the room gets quieter” sharper focus on cognitive tasks. Tool, not cycle.

Protocol implication: route matches goal

The clean protocol synthesis (consistent with the verified mechanism + practitioner observation):

Goal	Route	Dose	Cadence
Building structural baseline anxiety reduction	Injectable (SubQ)	300-600 mcg/day	10-week cycle, 5 days on / 2 days off
On-demand cognitive performance window	Intranasal spray	100-200 mcg per dose	As needed before deep-work / high-stakes sessions
Both: foundation + performance	Sequential	Injectable cycle first → off → intranasal as needed	Build the floor first, then perform on top of it

The two routes are different tools, not competing options. A user who tries injectable Selank expecting an acute “feel it” effect will be disappointed; the route they want for that experience is intranasal. A user who runs intranasal-only expecting structural baseline change won’t get the deep recalibration; the route they want for that is injectable.

Why the existing wiki said “stick with intranasal” — context

The original Selank wiki (“intranasal is the validated route — every published trial used intranasal”) was correct for the published human-trial evidence base (the Russian anxiety-disorder RCTs all used intranasal, which is the route Selank is approved as a prescription nasal spray for in Russia). The injectable route is well-supported in animal pharmacology for the GABA-mediated baseline-recalibration effect, and is widely used in the practitioner community for that purpose, but it doesn’t have its own published human RCT specifically for the SubQ delivery route. Both routes are legitimately used; they’re optimized for different goals.

The practitioner-camp counter-position — honest both-sides framing

Not every practitioner observes a clinically-meaningful difference between routes. Some content-creator practitioners report “I’ve used both routes and don’t see much difference”. This isn’t wrong as a subjective observation; it reflects the reality that most users running both routes are pursuing the same broad goal (cognitive support + anxiety reduction), so the receptor-target difference doesn’t surface as a distinctly-different felt experience. The verified mouse-study mechanism (Volkova 2018) remains the OHM editorial position — route does change which receptor the molecule preferentially engages. But that’s a structural mechanism finding, not a guarantee that every user will subjectively distinguish the two experiences. Three reasons subjective observation may not match the mechanism cleanly:

1. Same-goal usage. If you use both routes to chase the same general “I want to feel calmer and more focused” outcome, the dominant-receptor difference is muted because you’re not deliberately running an A/B test on the two specific functional dominances (slow systemic baseline shift vs acute neuroplasticity hit).
2. Individual receptor sensitivity variation. People with different baseline GABA/glutamate/serotonin/dopamine status will respond differently to either route. The cleanest route-change-receptor effect shows up most distinctly in users with specific baseline imbalances.
3. Dose + cadence asymmetry in real-world use. The mouse study used controlled dosing on both routes; real-world users often run intranasal at acute, on-demand cadences and injectable at cycled-daily cadences. The protocol differences confound the receptor-difference signal.

Practical implication: if you want to deliberately leverage the route-receptor distinction, use the protocol framework above (injectable for foundation, intranasal for performance window). If you’re using Selank casually for general support and don’t care about optimizing the receptor-target match, the practitioner-camp “use whatever’s convenient” position is also defensible.

What the research shows

Human / clinical: this is Selank’s strongest tier. Selank is one of the best-evidenced nootropic peptides in the KB at the human-trial level: 800+ patients across multiple controlled Russian trials, including formal RCTs in generalized anxiety disorder. The evidence comes from the Russian-affiliated institutional ecosystem and there’s no independent Western Phase 3 replication — that’s the honest caveat — but the data themselves are real, controlled, and replicated within that ecosystem over a decade-plus.

The landmark trials:

• GAD / neurasthenia vs. medazepam — Zozulia, Neznamov, Siuniakov et al. 2008 (n=62): Selank produced anxiolytic effect similar to medazepam with additional anti-asthenic (anti-fatigue) effects (PMID 18454096). This is the verified anchor for the “matches a benzodiazepine on anxiety” claim.
• vs. phenazepam (head-to-head, tolerability) — Medvedev, Tereshchenko et al. 2014 (n=60): Selank showed anxiolytic + nootropic effects comparable to phenazepam with better tolerability (PMID 25176261). The cognitive edge (benzo slows reaction time, Selank doesn’t) lives in this comparison.
• Combined-therapy optimization — Medvedev, Tereshchenko, Kost et al. 2015 (n=70): adding Selank to phenazepam reduced benzodiazepine side effects while keeping anxiolytic efficacy (PMID 26356395).
• Enkephalinase-inhibition mechanism (human + animal) — Zozulya, Kost et al. 2001 confirmed Selank inhibits enkephalin-degrading enzymes as a basis for its anxiolytic activity (PMID 11550013); Sokolov et al. 2002 replicated this in mice (PMID 12432865).
• Immunomodulation — Uchakina et al. 2008: Selank modulated Th1/Th2 cytokine balance in anxiety-asthenic patients (PMID 18577961); Ershov et al. 2009: antiviral activity against influenza via interferon-alpha induction (PMID 19882898) — the tuftsin-analog arm.

The specific “n=60 GAD RCT, 47% vs 34% HAM-A reduction at 300 mcg 3×/day” figures came from a lower-trust text-aggregation digest and have not been matched to a specific PubMed abstract — keep that exact number tagged until pinned. The verified trial record above supports the same qualitative conclusion (benzodiazepine-equivalent anxiolysis, better cognition/tolerability) on confirmed PMIDs.

Animal / preclinical: first-class evidence supporting the mechanism stack.

• BDNF upregulation in hippocampus + prefrontal cortex.
• Anxiolytic effect in standard rodent models (elevated plus maze, open field) with no sedation/motor impairment.
• Mood stabilization + anti-depressive effects in chronic-stress models.
• Cognitive enhancement on learning/memory tasks.
• Immunomodulatory effects (NK cell, IFN) in immune-challenge models.

Selank vs. Semax: the operational distinction. This is the cleanest single-source decision tree in the KB for the Russian-school cognitive peptides:

Profile	Selank	Semax
Effect	Calming + clarifying	Activating + sharpening
Best for	Anxiety, rumination, stress reactivity, sleep	Cognitive fog, low drive, attention, motivation
Onset of subjective effect	1-3 days	Hours to days
Mechanism focus	BDNF + enkephalin + monoamine normalization	ACTH(4-7) fragment → MC4/MC3 → BDNF/NGF
Caveat	Mild nasal irritation; secondary immune effect (caution with autoimmune disease)	Possible elevated baseline anxiety in sensitive users at higher doses
Stack	Co-administered at lower doses for mixed presentations — 100 mcg Semax + 100-200 mcg Selank intranasal	(Same — combine at lower doses)

Stack caveat: there is no controlled human trial of the Semax+Selank combination specifically — Russian clinical use co-administers them but the combination doesn’t have its own trial evidence. Trial each peptide individually before combining.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Route. Intranasal is the published-trial route — every Russian human RCT used intranasal Selank, and that’s where the clinical evidence lives. Subcutaneous injection is also widely used in the practitioner community and is validated in animal pharmacology, but with a different receptor target profile (GABA-dominant rather than NMDA-dominant — see Route changes the receptor above for the mechanism + protocol implications). The protocol below covers the intranasal route in detail; for injectable Selank protocols (used for slow systemic baseline recalibration over 10-week cycles), see the route-mechanism section above for the cadence + dose framework.

Reconstitution + concentration math. Selank is sold either as a pre-made nasal spray (commonly 0.15% = 1.5 mg/mL, or 0.3% / 3 mg/mL) or as a lyophilized powder reconstituted into a metered-dose spray. A pharmaceutical metered spray dispenses ~0.05 mL per actuation; at 1.5 mg/mL that’s 75 mcg per spray (so two sprays ≈ 150 mcg, between-nostril dosing common). exact per-actuation volume across compounded products.

The clean DIY nasal-spray recipe (added 2026-06-22): for users reconstituting their own from a lyophilized vial, the most-elegant arrangement is 10 mg vial + 5 mL sterile saline → 2 mg/mL concentration → ~0.1 mL per spray = 200 mcg per spray (5 mL bottle ≈ 50 sprays). Standard low/mid/high tier becomes a clean 1 / 2 / 3 sprays = 200 / 400 / 600 mcg.

Sterile saline vs bacteriostatic water — the choice that matters for daily intranasal use. Most peptide-dosing content defaults to bacteriostatic water (BAC water), which contains 0.9% benzyl alcohol as preservative. BAC water is the right choice for injectable preparations: the alcohol keeps the vial sterile across 28+ days and the trace amount injected SubQ doesn’t cause meaningful issues. But for daily intranasal use, benzyl alcohol is irritating to nasal mucosa over time. Sterile saline (or 0.9% sodium chloride irrigation solution) is closer to natural nasal-tissue isotonic chemistry and avoids the cumulative mucosal-irritation issue. The trade-off: saline has no preservative, so the reconstituted bottle must be refrigerated between uses and used within 7-14 days rather than the 28+ day BAC water vial life.

For occasional / on-demand intranasal use (the NMDA-side performance-window pattern), BAC water is probably fine — the brief intermittent exposure is mild. For daily long-term intranasal protocols, sterile saline is the better choice. Either is defensible; the trade-off is preservative-driven shelf life vs intranasal-mucosa friendliness.

One practical step often overlooked: generic aftermarket metered-dose nasal sprayers (Amazon, etc.) are NOT shipped sterile. Boil them briefly before first use to sterilize. One-time prep step that prevents introducing contaminants into the otherwise-sterile peptide solution.

Onset timing — three tiers worth setting expectations around (added 2026-06-24). The wiki’s earlier “1-3 days” framing collapses three genuinely-different timing patterns. Practitioner-camp tiering that lines up with the published mechanism work:

• Preventive antiviral / antimicrobial / antifungal sinus protection — effect is immediate on contact. Use the spray before exposure (mold-heavy environment, viral season, sinus-infection-prone period). Anchored in Ershov 2009 (PMID 19882898) — Selank’s interferon-alpha induction is the mechanism the intranasal route puts directly at the site of viral entry. for the use-case framing on top of the verified mechanism.
• Acute anxiety / GABA-mediated relief — within ~30 minutes of dose. This is the in-the-moment “bring it down” use case. Consistent with the intranasal-NMDA/GABAergic-pathway-onset window described in the Volkova receptor work and the existing 10-minute CSF-onset framing above.
• Long-term anxiety or sleep stabilization — 3-4 days to build a steady effect. This is the time-to-build window for the harder-anxiety cases. The wiki’s existing “1-3 days” RCT-anchored framing sits at the fast end of this range; 3-4 days is the practitioner-camp realistic upper-end.

Mold-exposed audience cross-reference: people whose brain fog traces to mycotoxin / mold environment exposure are a real OHM reader segment, and the sinus-antiviral mechanism plus Selank’s broader neuroinflammatory modulation make it a fit for that profile alongside the standard mold-detox foundation work. (Not a primary mold therapy — an adjunct that addresses the anxiety + cognitive-fog symptom cluster while the detox work runs.)

Community-standard protocol (converged across the published RCT dose + Russian clinical practice):

• Standard daily dose: 300-600 mcg/day, split 2-3× (100-200 mcg per dose, typically one spray per nostril per administration).
• Titration: Start at 100-200 mcg/day for the first 7 days; assess; increase if needed. Many users find 300 mcg/day adequate.
• Timing: Morning for daytime anxiety + cognitive support; evening for sleep-quality support. Afternoon/early-evening is a sensible practitioner-camp default — gives the brain a break from the day’s focus work before transitioning to family/recovery time, without dosing so late it interferes with sleep onset for the activation-sensitive subset of users.
• Cycle (Option A: the RCT pattern): 10-14 consecutive days on / 7-10 days off.
• Cycle (Option B: extended): 28 consecutive days / 2-week break. Trial data showed no tolerance development at day 28.
• No dose escalation required — same dose maintained efficacy across the trial duration. This is a real, distinguishing feature versus the dose-creep typical of benzodiazepines.

TRT compatibility. Selank shows no HPG axis effect, no SHBG effect — it’s safe to stack alongside any standard TRT protocol. Notable for the male performance/anti-aging audience that’s typically running testosterone optimization in parallel.

Stacking. The natural pair is Selank + Semax — calming + activating, used together at reduced individual doses for mixed anxiety-cognitive presentations. Selank also stacks well with foundational support: Glutathione for the oxidative-stress baseline, BPC-157 for systemic anti-inflammatory effects, and GHK-Cu for broader cellular repair signaling.

Side effects & management

Selank is one of the cleanest safety profiles in the entire peptide catalog. Across 800+ patient trial enrollments, no serious adverse events have been reported. The real-world AE cluster:

• Mild nasal irritation from the spray vehicle — the single most common AE. Usually trivial; rotate nostrils, hydrate the nasal mucosa.
• Mild headache in the first few days of a cycle; typically self-resolves.
• Sleep changes if dosed too close to sleep — Selank is mildly activating in some users (despite the anxiolytic effect), so AM/early PM dosing is the standard pattern unless you’re specifically using it for sleep-quality issues.
• No hepatotoxicity, no cardiovascular signals, no documented dependence pattern.

Caution: in active autoimmune conditions or while on immunosuppressant therapy, Selank’s tuftsin-analog immune-modulating effect may interact. Not a hard contraindication, but worth a conversation if you’re managing one of those conditions.

Storage: Refrigerate; protect from light; use within the compounding label window (typically 30-60 days post-reconstitution for the spray form).

Regulatory status

Russia: Approved by the Russian Ministry of Health for generalized anxiety disorder. US: Not FDA-approved for any indication. Not a controlled substance. Sold legally as a research chemical, “not for human consumption.” Not on the WADA prohibited list: notable for athletes. NOT available via 503A compounding pharmacies: on September 29, 2023, FDA added Selank acetate (TP-7) to its Category 2 bulk-drug-substances list, barring it from 503A compounding (Semax and DSIP/Emideltide were added in the same action). One nuance worth tracking: some peptides nominated alongside Selank had their nominations withdrawn in 2024, so the precise current status is worth re-checking — but as it stands Selank is research-channel-only in the US, not compoundable.

The Alyve product

Not in Alyve’s current launch catalog: flagged as a roadmap candidate. Selank is on the catalog-expansion shortlist alongside Semax as the natural Russian-nootropic-pair offering. The format that matches the clinical convention is a pre-made intranasal spray (0.15% or 0.3%).

The Alyve trust story still anchors every peptide decision: US-manufactured, third-party Freedom Diagnostics COAs, >99% purity verified across the launch catalog, identity-confirmed by HPLC-UV + LC-MS. The supply-chain story matters disproportionately for the Russian-school peptides specifically — counterfeit Selank and Semax are common in the gray market, and the typical buyer has no easy way to verify what they’re getting. A verified-COA vendor isn’t a luxury for this category; it’s the whole reason to buy from a vendor rather than a forum link.

Where to buy Selank today. Selank isn’t an Alyve SKU yet, but it’s now carried by BioLongevity Labs, a verified OHM affiliate partner with third-party COA testing: use code OHM-15 for 15% off. As with Semax, the Russian-nootropic category is gray-market-heavy and counterfeits are common, so the thing that decides whether a protocol works is identity-confirmed, COA-tested product — buy from a tested source. A peptide-literate clinician is also a solid route (provider directory).

Technical & analytical reference (chemistry & QC)

Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.

Field	Value
Molecular formula	C33H57N11O9 (PubChem CID 11765600)
Average MW	751.9 g/mol
CAS	129954-34-3
Sequence	TKPRPGP (Thr-Lys-Pro-Arg-Pro-Gly-Pro; tuftsin Thr-Lys-Pro-Arg + Pro-Gly-Pro tail)
HPLC purity criterion	RP-HPLC (C18, 210–220 nm, 0.1% TFA / acetonitrile) main peak ≥95%
MS identity	ESI-MS [M+H]⁺ m/z 752.9, [M+2H]²⁺ m/z 376.9; HRMS confirms C33H57N11O9
Counterion / net peptide	TFA salt from purification; AAA target ratios Thr:Lys:Arg:Gly 1:1:1:1 with Pro ×3; peptide content corrected for counterion + moisture
Storage / reconstitution	Lyophilized −20°C (or 2–8°C up to 6 mo), amber vial; reconstitute sterile/bacteriostatic water or PBS pH 7.4, gentle swirl; intranasal isotonic saline pH 6.0–7.4; stable 2–3 yr lyophilized
Degradation / stability	Peptide-bond hydrolysis and oxidation are the main paths; the C-terminal Pro-Gly-Pro resists carboxypeptidase (the design intent); Selank lacks Asn/Gln so classic deamidation is minimal

Primary-literature citation leads (PeptideBiologix; confirm before citing): Uchakina et al. J Neuroimmunol 2008 (PMID 18692909); Inozemtsev et al. Bull Exp Biol Med 2008 (GABA-A subunit expression, PMID 19099808 — relevant to the open GABA-A question above); Zolotarev et al. Biochemistry (Mosc) 2003 (ACTH(6-9)PGP stability, PMID 12857015); Volkova et al. Front Pharmacol 2016 (GABAergic gene-expression PCR array — 84 genes scanned, ~29 significantly changed by Selank alone at 1 h post-dose; PMID 26924987 — corrected 2026-06-24 from the previously-circulated 26903868, which is an unrelated aquaporin-2 paper); Zherdev et al. 2008 (GAD clinical efficacy, PMID 18607730)

Sources

• primary source for mechanism (triple pathway), the 60-patient GAD RCT, the medazepam head-to-head, dosing protocols, Selank-vs-Semax distinction, TRT compatibility, the GABA-A mechanism contradiction.
• Durst’s clinical-practice Selank-vs-Semax framing (calming/anxiety vs. activating/focus), intranasal-as-standard confirmation.
• Selank B/green + SECONDARY sleep grading.
• thepeptidelist.com directory entry; source of the now-verified Russian RCT PMIDs (18454096, 25176261, 26356395), the enkephalinase-mechanism PMIDs (11550013, 12432865), and the FDA-Category-2 (compounding-restricted) status flag.
• Morelli’s 15-min Selank/Semax nasal-vs-injectable deep-dive. Source for the “Route changes the receptor” section above. The central NMDA-vs-GABA route-dependent claim independently verified via Volkova et al. 2018 + follow-up Neurochemical Journal papers.
• DeMesquita’s 8-min Semax/Selank dosing walkthrough + the practitioner-camp counter-position on routes (“I don’t see much of a difference between injection and nasal”) surfaced honestly in the “practitioner-camp counter-position” subsection above. Reconciliation: the verified mouse-study mechanism remains the OHM editorial position; subjective observation in casual same-goal use often doesn’t surface the receptor-target distinction clearly. Both positions surfaced for honest both-sides framing.
• Holyfield’s 2:52 tactical Short on the specific mechanics of mixing Semax/Selank into a metered-dose nasal spray. Source for the “clean DIY nasal-spray recipe” (10 mg vial + 5 mL sterile saline → 200 mcg per spray) + the sterile-saline-vs-bacteriostatic-water trade-off for daily intranasal use + the boil-the-sprayer practical prep step, all added to the Reconstitution + concentration math section above.
• Regan Archibald (Ageless Future clinic chain) 10-min explainer focused on “how long does Selank take to work.” Source of the three-tier onset framing in the Real-world protocol section (preventive antiviral immediate / acute GABA ~30 min / long-term stabilization 3-4 days), the mold-exposure-audience cross-reference, the afternoon/early-evening daily-use timing recommendation, AND the verification-pass discovery that fixed the wrong Volkova 2016 (was citing PMID 26903868 — an unrelated aquaporin-2 paper — corrected to PMID 26924987). Two Archibald claims were checked against primary literature and NOT propagated: (a) the “52 genes turn on GABA production” line — Volkova 2016 actually reports ~29 genes at 1 h post-Selank (not 52), AND the mechanism is GABAergic neurotransmission (receptor subunits / transporters / signaling), NOT GABA synthesis; (b) the strengthened Zozulia 2008 Medazepam framing (“Selank faster + better long-term + no dependency risk”) — the Zozulia abstract supports only “similar to medazepam with additional anti-asthenic effects,” which is the wiki’s existing conservative summary. ✅ verified 2026-06-24.
• one practitioner ~49-min anxiety reconstruction video (2026-07-19). Source for: 5-HT1A receptor sensitivity framing added to monoamine normalization; vagal tone/NTS mechanism; neuroinflammation mechanism clarification (what Selank actually does vs. fabricated citations); anxiety cascade context in anxiety-protocol. All 7 one practitioner-specific paper citations failed verification — framework is real neuroscience; no fabricated citation text from this video was added to the wiki.
• FDA Category 2, Sept 29 2023: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
• Verified primary literature (route-of-administration receptor finding — added 2026-06-22):
  • Volkova A, Shadrina M, Kolomin T, et al. “Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/C and C57BL/6 mice.” 2018. PMID 29787664. ✅ verified 2026-06-22 — the anchor paper showing intraperitoneal Selank +38% GABA-A binding (frontal cortex) vs intranasal Selank +23% NMDA binding. Resolves the prior GABA-mechanism-contradiction flag — it’s the same molecule on two routes producing two different receptor signatures, not a literature inconsistency.
  • Andreeva LA, Kolomin TA, Slominsky PA, et al. “Predominance of Nootropic or Anxiolytic Effects of Selank, Semax, and Noopept Peptides Depending on the Route of Administration to BALB/c and С57BL/6 Mice.” Neurochemical Journal 2020. DOI 10.1134/S1819712420030113. ✅ verified 2026-06-22 — extends the route-dependent finding from Selank to Semax + Noopept.
  • Andreeva LA, et al. “Common and Specific Effects of Selank, Noopept, and Semax on the Glycine Site of the NMDA Receptor in BALB/c and C57Bl/6 Mice Brains.” Neurochemical Journal 2023. DOI 10.1134/S1819712423020174. ✅ verified 2026-06-22 — mechanistic follow-up pinning the glycine binding site as the route-dependent NMDA target.

Related: Semax · the Khavinson cognitive peptides (Pinealon, Cortagen) · Glutathione · BPC-157 · GHK-Cu · anxiety-protocol.